You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Changes in Hong Kong stocks | minimally invasive medical treatment has increased by more than 16%. The Medical Insurance Bureau says innovative medical devices will not be purchased with volume.
uSMART盈立智投 09-05 09:42

Minimally invasive medical care rose more than 16%. As of press time, it rose 16.38% to HK $17.9, with a turnover of HK $67.9862 million. Minimally invasive robots rose more than 7%, with a turnover of nearly HK $10 million.

On the face of the news, National Healthcare Security Administration issued "National Healthcare Security Administration's reply to recommendation No. 8427 of the Fifth session of the 13th National people's Congress" on September 1st, pointing out that in the process of centralized volume procurement, medical institutions are based on historical usage, combined with clinical use and medical technology progress to determine the procurement volume. As the clinical use of innovative medical devices is not yet mature and the amount of use is temporarily difficult to predict, it is still difficult to implement the quantity mode. In the process of centralized volume procurement, the proportion of volume is reasonably determined according to the characteristics of clinical use, the pattern of market competition and the number of selected enterprises, and a certain market is set aside to provide space for innovative products to open up the market.

Citic Construction Investment said in a statement that, based on the relevant policy views of the recent Medical Insurance Bureau, the agency believes that the policy of medical insurance for innovative devices is marginal: 1) the clinical use of innovative medical devices is not yet mature, and the use of innovative medical devices is difficult to estimate for the time being. it is difficult to implement the quantity method; 2) in the process of centralized volume procurement, set aside a certain market to provide space for innovative products to open up the market. 3) improve the networking mechanism of the centralized pharmaceutical procurement platform to help new medical devices participate in market transactions smoothly; 4) study and improve relevant policies to guide all localities to timely bring qualified innovative medical consumables into the scope of medical insurance payment according to procedures; 5) in the process of promoting the reform of DRG/DIP medical insurance payment methods, support innovative medical consumables in accordance with relevant regulations and procedures. Up to now, the State Drug Administration has approved the registration and listing of 173 innovative medical devices, mainly related to cardiovascular intervention, IVD, medical imaging, peripheral intervention, surgical robots, auxiliary diagnosis software, tumor treatment and other fields. This catalogue may be of reference significance for National Healthcare Security Administration to formulate health insurance payment policies related to innovative medical devices.

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account